Đang chuẩn bị liên kết để tải về tài liệu:
Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: A retrospective study

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modification and subsequent poor disease control. |